Replies to post #107734 on Biotech Values

[DewDiligence]

AVNR—"off-label usage in a broader patient pool is likely."

That statement is unduly vague. How much off-label use? In which indications?

A serious attempt to answer these questions will show that some of the peak-sales forecasts you’re reading today are unrealistic, IMO.